GPT and hepatotoxicity: Hepatic impairment was reported in 33.64% of patients in the PMS study (as a priority investigation item), while the pooled analysis reported up to 60% of patients with liver laboratory test abnormalities, 0.7% of patients with hepatotoxicity, 48.3% of patients with increased ALT and 39.5% of patients with increased aspartate aminotransferase (AST).